Riley Exploration Permian, Inc. is rated a Buy due to strong production and improved balance sheet. Learn more about REPX ...

VKTX remains a Buy for its cheap FY2030 EV/Sales valuations of 2.28x, the strong clinical trial results exceeding legacy ...

Covering some maternity leave, doing monthly accounts - 3 months into the next year but previous year remains open in client software.

CEO Lip-Bu Tan said 2025 marked a pivotal turning point for the chipmaker as major AI funding deals and a sharp stock rally ...

The company boasts a fortress-like balance sheet with significant cash reserves ($8.4 billion in cash at the end of Q3 2025) ...

Lipocine ( ($LPCN) ) has shared an announcement. On December 16, 2025, Lipocine announced that its Phase 3 clinical trial for LPCN 1154, an oral ...

Morgans healthcare analysts give Stockhead readers their top picks for 2026 after a tough year for the sector.

Amazon ( AMZN +0.06%) continues to underscore the strength of its business and deliver fantastic growth for long-term ...

TheFly reported on December  16 that Oppenheimer raised its price target on WVE to $32 from $24 while maintaining an ...

DBV Technologies (ENXTPA:DBV) has scheduled a special call to unpack the VITESSE trial results and outline next steps for its Viaskin Peanut program, putting fresh attention on the company’s late ...

Networth2B, a small business accounting solutions provider specializing in local apps that stay on the user's device, announced the addition of new billing features for professional services providers ...

The company is financially solid, with over $2 billion in cash and healthy profit margins. While the stock isn’t cheap, its ...